SYK
Another day, another medtech flex
Stryker is writing a big check — up to $835 million — to acquire Amplitude Vascular Systems, a startup built around a next-gen hydraulic intravascular lithotripsy platform. Translation: it’s buying tech that helps treat calcified peripheral arterial disease, which is exactly the kind of unglamorous-but-valuable medical plumbing that can turn into serious business.
Why this matters
For Stryker, this isn’t just trophy-hunting. It’s a clean way to add more firepower in vascular devices, where better tools can mean better clinical outcomes and a fatter revenue stream. In medtech, that’s the dream: build a product that doctors want, patients need, and competitors have to chase.
The bigger picture
The deal also says something about the ecosystem around Stryker’s Michigan backyard. BioStar Capital called this a “pre-FDA exit,” which is VC-speak for: we built it, we sold it, everyone gets to tell a victory-lap story at the conference panel.
- Stryker gets a technology boost in a high-need treatment area.
- AVS gets a big-company runway instead of the startup treadmill.
- Investors get another reminder that M&A is very much alive in medtech when the target plugs a real clinical gap.
Big picture: Stryker isn’t just buying growth — it’s buying optionality in a market where better catheter tech can be the difference between “nice slide deck” and actual moat.